InterMune Lowered to Hold at Stifel Nicolaus (ITMN)
InterMune (NASDAQ:ITMN) was downgraded by stock analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report issued on Monday, TheFlyOnTheWall.com reports. They currently have a $53.00 price target on the stock, down from their previous price target of $53.80. Stifel Nicolaus’ price target indicates a potential downside of 1.49% from the stock’s previous close.
In other InterMune news, EVP Paul D. Arata sold 7,500 shares of InterMune stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $50.00, for a total value of $375,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
A number of other analysts have also recently weighed in on ITMN. Analysts at Leerink Swann raised their price target on shares of InterMune from $53.00 to $74.00 in a research note on Monday. Separately, analysts at Robert W. Baird raised their price target on shares of InterMune from $50.00 to $74.00 in a research note on Monday. They now have an “outperform” rating on the stock. Finally, analysts at Wells Fargo & Co. downgraded shares of InterMune from an “outperform” rating to a “market perform” rating in a research note on Thursday. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $53.42.
Shares of InterMune (NASDAQ:ITMN) traded up 35.51% on Monday, hitting $72.905. 41,930,076 shares of the company’s stock traded hands. InterMune has a one year low of $10.95 and a one year high of $55.24. The stock’s 50-day moving average is $45.86 and its 200-day moving average is $36.13. The company’s market cap is $7.871 billion.
InterMune (NASDAQ:ITMN) last released its earnings data on Wednesday, August 6th. The company reported ($0.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter last year, the company posted ($0.77) earnings per share. InterMune’s revenue was up 141.2% compared to the same quarter last year. On average, analysts predict that InterMune will post $-2.75 earnings per share for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Receive News & Ratings for InterMune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterMune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.